Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

Cloak™ and Dagger™ Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T™ Cells Data from Preclinical Study of Cloak™ Technology Highlights Ability to Engineer…

Continue ReadingAllogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic Cancers SOUTH SAN…

Continue ReadingAllogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

Comprehensive Review of Overall Treatment Safety Profile of our ALLO-501/501A Candidate Used in Conjunction with Propriety Lymphodepletion with Investigational ALLO-647 from the Phase 1 ALPHA/ALPHA2 Studies Translational Overview of Patient…

Continue ReadingAllogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology